TAK Takeda Pharmaceutical Company L

$18.26▲ +0.83% Healthcare Other
After hours $18.26▼ -0.04% Sep 11, 4:00 PM ET
Volume 2.15M Avg Volume (10D) 1.97M
Key Metrics & Fundamentals
Market Cap
$58.31B
P/E Ratio
42.2
Div Yield
3.40%
52W Range
12.99 - 18.90
% vs 50 MA
4.50%
% vs 200 MA
8.40%
RSI-14
57.0
MACD Histogram
-0.0500
Beta (1Y vs SPY)
0.19
Free Cash Flow
$127.60M
Gross Rev
$1.22T
Gross Profit
$813.22B
EBITDA
$337.49B
COGS
$406.68B
Operating Exp
$611.81B
Operating Income
$201.42B
EBIT
$201.42B
Pretax Income
$162.72B
Net Income
$113.20B
EPS (Diluted)
35.27
Price & Volume History
Loading chart…
Recent News
Andy Plump, architect of Takeda’s R&D overhaul, to retire next year
BioPharma Dive · Sep 10, 2026 11:24 AM
Trialbee to Present with Takeda, Showcase AI for Clinical Sites, and Unveil AI-Powered Patient Screening at DPHARM 2026
Business Wire · Sep 9, 2026 1:00 PM
New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life
Business Wire · Sep 9, 2026 12:24 PM
Onco360® Has Been Selected as Part of an Ultra-Narrow Specialty Pharmacy Network for MIMRYLO™ (rusfertide)
GlobeNewswire · Sep 9, 2026 11:00 AM
Protagonist Therapeutics Announces $300 Million Share Repurchase Program
ACCESS Newswire · Sep 8, 2026 8:05 PM
Ulcerative Colitis Market Outlook: 5 Late-Stage Drug Candidates to Watch | DelveInsight
GlobeNewswire · Sep 7, 2026 5:00 PM
MIMRYLO Approval Triggered $275M Payments for Protagonist (PTGX). Are Royalties the Better Commercial Model?
Insider Monkey · Sep 4, 2026 4:14 PM
Takeda Pharmaceutical Insider Sold Shares Worth $2,148,372, According to a Recent SEC Filing
MT Newswires · Sep 4, 2026 7:29 AM
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
Zacks · Sep 2, 2026 1:40 PM
2026 Complement Inhibitors Market Analysis Report (2nd Edition) Featuring Amgen, CSL Behring, Innovent Biologics, Novartis, Regeneron, Roche, Sanofi, Takeda, UCB
GlobeNewswire · Sep 2, 2026 11:17 AM
Financial Overview - Income Statement Quarterly

See TAK's money flow as a full page

Social Sentiment
Avg +0.58 · 4 posts
Biotech with strong growth and profitability : NBIX
r/stocks · Jan 28, 2025
The post highlights positive developments like drug approvals and partnerships, suggesting investor interest in the company's growth.
positive +0.60
NewsIt’s the kind of day I particularly enjoy, as some sectors are showing strength across the board. Today, it’s clear that healthcare, energy, and consumer cyclicals are leading the charge, with companies like SNY (+0.95%) and EQNR (+1.56%) making noticeable moves.
r/StockMarket · Dec 27, 2024
Associated with a positive trend in the healthcare sector.
positive +0.50
NewsDiscussionTakeda Pharmaceutical
r/wallstreetbets · Dec 6, 2024
The post highlights promising early trial results and a potential new treatment standard, demonstrating a positive outlook for the stock.
positive +0.60
The most undervalued stock in the stock market? [DD post]
r/stocks · Sep 18, 2024
The post highlights positive data and a significant stock increase for CADL, indicating a bullish outlook.
positive +0.60
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙